v3.26.1
Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Revenue $ 75,253 $ 27,767 $ 413,023 $ 572,976
Operating expenses:        
Research and development 198,223 162,368 548,679 432,472
Selling, general and administrative 47,123 30,949 134,888 86,264
Total operating expenses 245,346 193,317 683,567 518,736
Operating (loss) income (170,093) (165,550) (270,544) 54,240
Other income (expense):        
Interest income 16,935 11,019 43,496 28,236
Interest expense (24,562) (24,382) (70,913) (67,667)
Loss on equity method investment (2,470) 0 (9,190) 0
Gain on VIE's sale of IPR&D assets 0 0 19,000 0
Other, net 1,285 (176) (52) 603
Total other (expense) income (8,812) (13,539) (17,659) (38,828)
(Loss) income before income tax expense (benefit) and noncontrolling interest (178,905) (179,089) (288,203) 15,412
Income tax expense (benefit) 11 (437) 46 1,419
Net (loss) income including noncontrolling interest (178,916) (178,652) (288,249) 13,993
Net income (loss) attributable to noncontrolling interest, net of tax 15,364 (3,411) 7,956 (8,126)
Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. $ (194,280) $ (175,241) $ (296,205) $ 22,119
Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:        
Basic (in dollars per share) $ (1.36) $ (1.26) $ (2.10) $ 0.17
Diluted (in dollars per share) $ (1.36) $ (1.26) $ (2.10) $ 0.17
Weighted-average shares used in calculating        
Basic (in shares) 143,378 139,039 141,331 132,385
Diluted (in shares) 143,378 139,039 141,331 133,352
Comprehensive (loss) income:        
Net (loss) income including noncontrolling interest $ (178,916) $ (178,652) $ (288,249) $ 13,993
Other comprehensive (loss) income, net of tax:        
Unrealized gains (losses) on available-for-sale securities, net (2,254) 876 (9,042) 1,022
Foreign currency translation adjustments 487 91 1,588 (415)
Total other comprehensive income (loss) (1,767) 967 (7,454) 607
Comprehensive (loss) income (180,683) (177,685) (295,703) 14,600
Comprehensive income (loss) attributable to noncontrolling interest 15,573 (3,411) 8,609 (8,126)
Comprehensive (loss) income attributable to Arrowhead Pharmaceuticals, Inc. $ (196,256) $ (174,274) $ (304,312) $ 22,726